A Parkinson’s disease (PD) case with underlying cerebral small vessel disease (CSVD)
Objective: Emphasis of CSVD in PD through clinical-pathological correlation study. Background: PD affects 1.7%, while CSVD affects about 45% [1], of the population aged over…Parkinson’s disease and osteocalcin pilot study: Is there a protective role of bone in neurodegeneration?
Objective: To characterize the relationship between the bone-derived hormone osteocalcin (OCN) and Parkinson’s disease (PD) in humans, and explore sex and treatment differences. Background: The…Neuroimaging of anxiety in Parkinson’s disease: a systematic review
Objective: The aim of this systematic review was 1) to identify the brain regions involved in anxiety in Parkinson's disease (PD) based on neuroimaging studies,…Clinical and neurological features of the course of parkinsonism in the presence of chronic renal disease
Objective: To study the clinical and neurological features of the course of parkinsonism in chronic renal disease. Background: Under our supervision were 30 patients with…IncobotulinumtoxinA to treat sialorrhea in Parkinson’s disease: A real-life study
Objective: We evaluate the long-term efficacy and safety of incobotulinumtoxinA injections in advanced Parkinson’s disease (PD) patients suffering from sialorrhea (10 injection cycles into the…Assessing the Safety and Tolerability of ABBV-951 (Foscarbidopa/Foslevodopa) in Advanced Parkinson’s Disease Patients During a 52-Week Phase 3 Study: Study Design and Updated Patient Baseline Characteristics
Objective: To evaluate the local and systemic safety and tolerability of ABBV-951 (foscarbidopa/foslevodopa) delivered 24 h/day as a continuous subcutaneous infusion (CSCI) for up to…Reduction of OFF time with apomorphine infusion during hours of pump use: Analysis from a Phase III, open-label study
Objective: Evaluate the efficacy of apomorphine (APO) infusion in reducing OFF time during the hours of pump use in PD patients with motor fluctuations inadequately…Transcutaneous magnetic spinal cord stimulation for freezing of gait in Parkinson’s disease (PD)
Objective: To study the safety and efficacy of transcutaneous magnetic spinal cord stimulation (SCS) on freezing of gait (FoG) and other motor symptoms in a…Oral Venglustat in Parkinson’s Disease Patients With a GBA Mutation: Study Design of Part 2 of the MOVES-PD Trial and Patient Characteristics
Objective: Describe the study design of Part 2 of the MOVES-PD trial (NCT02906020), and report patient characteristics. Background: Mutations in the glucocerebrosidase (GBA) gene are…Daily Time-Course of Efficacy of Continuous Subcutaneous Infusion of Foslevodopa/foscarbidopa in Advanced Parkinson’s Disease Patients from a Phase 1b Study
Objective: Characterize and compare the time-course of Parkinson’s disease (PD) symptoms following 24h/day continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa and oral levodopa/carbidopa (LD/CD). Background: As…
- « Previous Page
- 1
- …
- 69
- 70
- 71
- 72
- 73
- …
- 149
- Next Page »